Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) Operating Margin (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Operating Margin for 11 consecutive years, with 428.86% as the latest value for Q4 2025.

  • Quarterly Operating Margin rose 63101.0% to 428.86% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 651.67% through Dec 2025, up 27143.0% year-over-year, with the annual reading at 651.67% for FY2025, 27143.0% up from the prior year.
  • Operating Margin for Q4 2025 was 428.86% at Intellia Therapeutics, up from 808.86% in the prior quarter.
  • The five-year high for Operating Margin was 212.18% in Q4 2021, with the low at 23997.67% in Q3 2021.
  • Average Operating Margin over 5 years is 2093.34%, with a median of 808.86% recorded in 2025.
  • The sharpest move saw Operating Margin plummeted -2387120bps in 2021, then skyrocketed 2320217bps in 2022.
  • Over 5 years, Operating Margin stood at 212.18% in 2021, then crashed by -31bps to 278.7% in 2022, then plummeted by -292bps to 1093.29% in 2023, then rose by 3bps to 1059.86% in 2024, then skyrocketed by 60bps to 428.86% in 2025.
  • According to Business Quant data, Operating Margin over the past three periods came in at 428.86%, 808.86%, and 772.17% for Q4 2025, Q3 2025, and Q2 2025 respectively.